Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.

Veenstra SJ, Rueeger H, Voegtle M, Lueoend R, Holzer P, Hurth K, Tintelnot-Blomley M, Frederiksen M, Rondeau JM, Jacobson L, Staufenbiel M, Neumann U, Machauer R.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2195-2200. doi: 10.1016/j.bmcl.2018.05.003. Epub 2018 May 3.

PMID:
29764741
3.

Innate immune memory in the brain shapes neurological disease hallmarks.

Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, Wagner J, Häsler LM, Wild K, Skodras A, Blank T, Staszewski O, Datta M, Centeno TP, Capece V, Islam MR, Kerimoglu C, Staufenbiel M, Schultze JL, Beyer M, Prinz M, Jucker M, Fischer A, Neher JJ.

Nature. 2018 Apr;556(7701):332-338. doi: 10.1038/s41586-018-0023-4. Epub 2018 Apr 11.

4.

Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease.

Rasmussen J, Mahler J, Beschorner N, Kaeser SA, Häsler LM, Baumann F, Nyström S, Portelius E, Blennow K, Lashley T, Fox NC, Sepulveda-Falla D, Glatzel M, Oblak AL, Ghetti B, Nilsson KPR, Hammarström P, Staufenbiel M, Walker LC, Jucker M.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13018-13023. doi: 10.1073/pnas.1713215114. Epub 2017 Nov 20.

5.

BACE inhibition-dependent repair of Alzheimer's pathophysiology.

Keskin AD, Kekuš M, Adelsberger H, Neumann U, Shimshek DR, Song B, Zott B, Peng T, Förstl H, Staufenbiel M, Nelken I, Sakmann B, Konnerth A, Busche MA.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):8631-8636. doi: 10.1073/pnas.1708106114. Epub 2017 Jul 24.

6.

Aβ seeding potency peaks in the early stages of cerebral β-amyloidosis.

Ye L, Rasmussen J, Kaeser SA, Marzesco AM, Obermüller U, Mahler J, Schelle J, Odenthal J, Krüger C, Fritschi SK, Walker LC, Staufenbiel M, Baumann F, Jucker M.

EMBO Rep. 2017 Sep;18(9):1536-1544. doi: 10.15252/embr.201744067. Epub 2017 Jul 12.

7.

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.

Schelle J, Häsler LM, Göpfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA.

Alzheimers Dement. 2017 Jun;13(6):701-709. doi: 10.1016/j.jalz.2016.09.005. Epub 2016 Oct 14.

PMID:
27750032
8.

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M.

Neuron. 2016 Jul 20;91(2):494-496. doi: 10.1016/j.neuron.2016.07.007. Epub 2016 Jul 20. No abstract available.

9.

Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor-treated APP transgenic mice.

Beckmann N, Doelemeyer A, Zurbruegg S, Bigot K, Theil D, Frieauff W, Kolly C, Moulin P, Neddermann D, Kreutzer R, Perrot L, Brzak I, Jacobson LH, Staufenbiel M, Neumann U, Shimshek DR.

Neurobiol Aging. 2016 Sep;45:50-60. doi: 10.1016/j.neurobiolaging.2016.05.009. Epub 2016 May 17.

10.

Highly potent intracellular membrane-associated Aβ seeds.

Marzesco AM, Flötenmeyer M, Bühler A, Obermüller U, Staufenbiel M, Jucker M, Baumann F.

Sci Rep. 2016 Jun 17;6:28125. doi: 10.1038/srep28125.

11.

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M.

Neuron. 2016 Jul 6;91(1):56-66. doi: 10.1016/j.neuron.2016.05.018. Epub 2016 Jun 9. Erratum in: Neuron. 2016 Jul 20;91(2):494-496.

12.

Conversion of Synthetic Aβ to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model.

Novotny R, Langer F, Mahler J, Skodras A, Vlachos A, Wegenast-Braun BM, Kaeser SA, Neher JJ, Eisele YS, Pietrowski MJ, Nilsson KP, Deller T, Staufenbiel M, Heimrich B, Jucker M.

J Neurosci. 2016 May 4;36(18):5084-93. doi: 10.1523/JNEUROSCI.0258-16.2016.

13.

Co-expression of truncated and full-length tau induces severe neurotoxicity.

Ozcelik S, Sprenger F, Skachokova Z, Fraser G, Abramowski D, Clavaguera F, Probst A, Frank S, Müller M, Staufenbiel M, Goedert M, Tolnay M, Winkler DT.

Mol Psychiatry. 2016 Dec;21(12):1790-1798. doi: 10.1038/mp.2015.228. Epub 2016 Feb 2.

14.

Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia.

Van der Jeugd A, Vermaercke B, Halliday GM, Staufenbiel M, Götz J.

Neurobiol Learn Mem. 2016 Apr;130:34-43. doi: 10.1016/j.nlm.2016.01.007. Epub 2016 Jan 28.

PMID:
26827932
15.

Statin Therapy and the Development of Cerebral Amyloid Angiopathy--A Rodent in Vivo Approach.

Reuter B, Venus A, Grudzenski S, Heiler P, Schad L, Staufenbiel M, Hennerici MG, Fatar M.

Int J Mol Sci. 2016 Jan 19;17(1). pii: E126. doi: 10.3390/ijms17010126.

16.

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Busche MA, Staufenbiel M, Willem M, Haass C, Förstl H.

Nervenarzt. 2016 Nov;87(11):1163-1174. Review. German.

PMID:
26781314
17.

Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.

Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Förstl H, Konnerth A.

Nat Neurosci. 2015 Dec;18(12):1725-7. doi: 10.1038/nn.4163. Epub 2015 Nov 9.

PMID:
26551546
18.

Persistence of Aβ seeds in APP null mouse brain.

Ye L, Fritschi SK, Schelle J, Obermüller U, Degenhardt K, Kaeser SA, Eisele YS, Walker LC, Baumann F, Staufenbiel M, Jucker M.

Nat Neurosci. 2015 Nov;18(11):1559-61. doi: 10.1038/nn.4117. Epub 2015 Sep 9.

PMID:
26352792
19.

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH.

Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8.

20.

Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties.

Skachokova Z, Sprenger F, Breu K, Abramowski D, Clavaguera F, Hench J, Staufenbiel M, Tolnay M, Winkler DT.

Curr Alzheimer Res. 2015;12(9):886-91.

PMID:
26159190
21.

Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice.

Balakrishnan K, Rijal Upadhaya A, Steinmetz J, Reichwald J, Abramowski D, Fändrich M, Kumar S, Yamaguchi H, Walter J, Staufenbiel M, Thal DR.

Acta Neuropathol Commun. 2015 Jul 4;3:41. doi: 10.1186/s40478-015-0217-z.

22.

Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.

Maia LF, Kaeser SA, Reichwald J, Lambert M, Obermüller U, Schelle J, Odenthal J, Martus P, Staufenbiel M, Jucker M.

EMBO Mol Med. 2015 Jul;7(7):895-903. doi: 10.15252/emmm.201505026.

23.

Endogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice.

Mahler J, Morales-Corraliza J, Stolz J, Skodras A, Radde R, Duma CC, Eisele YS, Mazzella MJ, Wong H, Klunk WE, Nilsson KPR, Staufenbiel M, Mathews PM, Jucker M, Wegenast-Braun BM.

Neurobiol Aging. 2015 Jul;36(7):2241-2247. doi: 10.1016/j.neurobiolaging.2015.03.011. Epub 2015 Mar 25.

24.

Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration.

van Eersel J, Stevens CH, Przybyla M, Gladbach A, Stefanoska K, Chan CK, Ong WY, Hodges JR, Sutherland GT, Kril JJ, Abramowski D, Staufenbiel M, Halliday GM, Ittner LM.

Neuropathol Appl Neurobiol. 2015 Dec;41(7):906-25. doi: 10.1111/nan.12233. Epub 2015 May 30.

PMID:
25763777
25.

An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.

Kizuka Y, Kitazume S, Fujinawa R, Saito T, Iwata N, Saido TC, Nakano M, Yamaguchi Y, Hashimoto Y, Staufenbiel M, Hatsuta H, Murayama S, Manya H, Endo T, Taniguchi N.

EMBO Mol Med. 2015 Feb;7(2):175-89. doi: 10.15252/emmm.201404438.

26.

Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion.

Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, Calaminus C, Stahlschmidt A, Ye L, Burnet M, Stiller D, Sabri O, Reischl G, Staufenbiel M, Garaschuk O, Jucker M, Pichler BJ.

Nat Med. 2014 Dec;20(12):1485-92. doi: 10.1038/nm.3734. Epub 2014 Nov 10.

PMID:
25384087
27.

Highly potent soluble amyloid-β seeds in human Alzheimer brain but not cerebrospinal fluid.

Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D, Kaminski CF, Winkler DT, Maetzler W, Keyvani K, Spitzer P, Wiltfang J, Kaminski Schierle GS, Zetterberg H, Staufenbiel M, Jucker M.

Brain. 2014 Nov;137(Pt 11):2909-2915. doi: 10.1093/brain/awu255. Epub 2014 Sep 10.

28.

Multiple factors contribute to the peripheral induction of cerebral β-amyloidosis.

Eisele YS, Fritschi SK, Hamaguchi T, Obermüller U, Füger P, Skodras A, Schäfer C, Odenthal J, Heikenwalder M, Staufenbiel M, Jucker M.

J Neurosci. 2014 Jul 30;34(31):10264-73. doi: 10.1523/JNEUROSCI.1608-14.2014.

29.

Deficiency of patched 1-induced Gli1 signal transduction results in astrogenesis in Swedish mutated APP transgenic mice.

He P, Staufenbiel M, Li R, Shen Y.

Hum Mol Genet. 2014 Dec 15;23(24):6512-27. doi: 10.1093/hmg/ddu370. Epub 2014 Jul 15.

30.

Thrombolysis in experimental cerebral amyloid angiopathy and the risk of secondary intracerebral hemorrhage.

Reuter B, Grudzenski S, Chatzikonstantinou E, Meairs S, Ebert A, Heiler P, Schad LR, Staufenbiel M, Hennerici MG, Fatar M.

Stroke. 2014 Aug;45(8):2411-6. doi: 10.1161/STROKEAHA.113.004483. Epub 2014 Jul 8.

PMID:
25005438
31.

Genetic deletion of TNFRII gene enhances the Alzheimer-like pathology in an APP transgenic mouse model via reduction of phosphorylated IκBα.

Jiang H, He P, Xie J, Staufenbiel M, Li R, Shen Y.

Hum Mol Genet. 2014 Sep 15;23(18):4906-18. doi: 10.1093/hmg/ddu206. Epub 2014 May 13.

32.

High efficiency cell-specific targeting of cytokine activity.

Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De Koker S, Piehler J, Tavernier J, Uzé G.

Nat Commun. 2014;5:3016. doi: 10.1038/ncomms4016.

PMID:
24398568
33.

Membrane-anchored Aβ accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice.

Nagarathinam A, Höflinger P, Bühler A, Schäfer C, McGovern G, Jeffrey M, Staufenbiel M, Jucker M, Baumann F.

J Neurosci. 2013 Dec 4;33(49):19284-94. doi: 10.1523/JNEUROSCI.2542-13.2013.

34.

The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice.

Rijal Upadhaya A, Scheibe F, Kosterin I, Abramowski D, Gerth J, Kumar S, Liebau S, Yamaguchi H, Walter J, Staufenbiel M, Thal DR.

Acta Neuropathol Commun. 2013 Nov 18;1:77. doi: 10.1186/2051-5960-1-77.

35.

Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides.

Rueeger H, Lueoend R, Machauer R, Veenstra SJ, Jacobson LH, Staufenbiel M, Desrayaud S, Rondeau JM, Möbitz H, Neumann U.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6. doi: 10.1016/j.bmcl.2013.07.071. Epub 2013 Aug 9.

PMID:
23981898
36.

Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice.

Paganetti P, Reichwald J, Bleckmann D, Abramowski D, Ammaturo D, Barske C, Danner S, Molinari M, Müller M, Papin S, Rabe S, Schmid P, Staufenbiel M.

Neurobiol Aging. 2013 Dec;34(12):2866-78. doi: 10.1016/j.neurobiolaging.2013.06.013. Epub 2013 Jul 17.

PMID:
23870837
37.

Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.

Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M.

Sci Transl Med. 2013 Jul 17;5(194):194re2. doi: 10.1126/scitranslmed.3006446.

38.

Amyloid precursor protein mutation disrupts reproductive experience-enhanced normal cognitive development in a mouse model of Alzheimer's disease.

Cui J, Jothishankar B, He P, Staufenbiel M, Shen Y, Li R.

Mol Neurobiol. 2014 Feb;49(1):103-12. doi: 10.1007/s12035-013-8503-x. Epub 2013 Jul 14.

39.

Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.

Deng Y, Wang Z, Wang R, Zhang X, Zhang S, Wu Y, Staufenbiel M, Cai F, Song W.

Eur J Neurosci. 2013 Jun;37(12):1962-9. doi: 10.1111/ejn.12235.

PMID:
23773065
40.

Brain homogenates from human tauopathies induce tau inclusions in mouse brain.

Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9535-40. doi: 10.1073/pnas.1301175110. Epub 2013 May 20.

41.

Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. [corrected].

Sirko S, Behrendt G, Johansson PA, Tripathi P, Costa M, Bek S, Heinrich C, Tiedt S, Colak D, Dichgans M, Fischer IR, Plesnila N, Staufenbiel M, Haass C, Snapyan M, Saghatelyan A, Tsai LH, Fischer A, Grobe K, Dimou L, Götz M.

Cell Stem Cell. 2013 Apr 4;12(4):426-39. doi: 10.1016/j.stem.2013.01.019. Erratum in: Cell Stem Cell. 2013 May 2;12(5):629.

42.

Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.

Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S, Saido TC.

Sci Rep. 2013;3:1472. doi: 10.1038/srep01472.

43.

Chronic administration of anti-stroke herbal medicine TongLuoJiuNao reduces amyloidogenic processing of amyloid precursor protein in a mouse model of Alzheimer's disease.

He P, Li P, Hua Q, Liu Y, Staufenbiel M, Li R, Shen Y.

PLoS One. 2013;8(3):e58181. doi: 10.1371/journal.pone.0058181. Epub 2013 Mar 5.

44.

Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease.

He P, Cheng X, Staufenbiel M, Li R, Shen Y.

PLoS One. 2013;8(2):e55091. doi: 10.1371/journal.pone.0055091. Epub 2013 Feb 6.

45.

Brain endogenous estrogen levels determine responses to estrogen replacement therapy via regulation of BACE1 and NEP in female Alzheimer's transgenic mice.

Li R, He P, Cui J, Staufenbiel M, Harada N, Shen Y.

Mol Neurobiol. 2013 Jun;47(3):857-67. doi: 10.1007/s12035-012-8377-3. Epub 2012 Nov 20.

46.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

PMID:
22677258
47.

Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease.

Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8740-5. doi: 10.1073/pnas.1206171109. Epub 2012 May 16.

48.

Role of hippocalcin in mediating Aβ toxicity.

Lim YA, Giese M, Shepherd C, Halliday G, Kobayashi M, Takamatsu K, Staufenbiel M, Eckert A, Götz J.

Biochim Biophys Acta. 2012 Aug;1822(8):1247-57. doi: 10.1016/j.bbadis.2012.04.007. Epub 2012 Apr 20.

49.

Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease.

Grienberger C, Rochefort NL, Adelsberger H, Henning HA, Hill DN, Reichwald J, Staufenbiel M, Konnerth A.

Nat Commun. 2012 Apr 10;3:774. doi: 10.1038/ncomms1783.

50.

Triple-color super-resolution imaging of live cells: resolving submicroscopic receptor organization in the plasma membrane.

Wilmes S, Staufenbiel M, Lisse D, Richter CP, Beutel O, Busch KB, Hess ST, Piehler J.

Angew Chem Int Ed Engl. 2012 May 14;51(20):4868-71. doi: 10.1002/anie.201200853. Epub 2012 Apr 5.

PMID:
22488831

Supplemental Content

Loading ...
Support Center